Hemolytic anemia and agranulocytosis associated with the administration of the papa-amino-benzene sulfonamide group of drugs

Lucile E. Loseke
University of Nebraska Medical Center

This manuscript is historical in nature and may not reflect current medical research and practice. Search PubMed for current research.

Follow this and additional works at: https://digitalcommons.unmc.edu/mdtheses

Part of the Medical Education Commons

Recommended Citation
Loseke, Lucile E., "Hemolytic anemia and agranulocytosis associated with the administration of the papa-amino-benzene sulfonamide group of drugs" (1940). MD Theses. 816.
https://digitalcommons.unmc.edu/mdtheses/816

This Thesis is brought to you for free and open access by the Special Collections at DigitalCommons@UNMC. It has been accepted for inclusion in MD Theses by an authorized administrator of DigitalCommons@UNMC. For more information, please contact digitalcommons@unmc.edu.
HEMOLYTIC ANEMIA AND AGRANULOCYTOSIS
ASSOCIATED WITH THE ADMINISTRATION OF
THE PARA-AMINO-BENZENE SULFONAMIDE
GROUP OF DRUGS

by

Lucile Loseke

Senior Thesis

Presented to
The College of Medicine
University of Nebraska
Omaha
1940
# TABLE OF CONTENTS

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Introduction</td>
<td>1</td>
</tr>
<tr>
<td>The Results of Experimental Work With Animals</td>
<td>5</td>
</tr>
<tr>
<td>Agranulocytosis and Hemolytic Anemia: Sensitivity Reactions of the Bone Marrow</td>
<td>17</td>
</tr>
<tr>
<td>Introduction</td>
<td>17</td>
</tr>
<tr>
<td>Hemolytic Anemia</td>
<td>17</td>
</tr>
<tr>
<td>Agranulocytosis</td>
<td>19</td>
</tr>
<tr>
<td>Hemolytic Anemia Associated with Sulfanilamide and Related Compounds</td>
<td>32</td>
</tr>
<tr>
<td>Introduction</td>
<td>32</td>
</tr>
<tr>
<td>Progressive Hemolytic Anemia</td>
<td>32</td>
</tr>
<tr>
<td>Acute Hemolytic Anemia</td>
<td>34</td>
</tr>
<tr>
<td>Leukopenia and Agranulocytosis Associated with Sulfanilamide and Related Drugs</td>
<td>40</td>
</tr>
<tr>
<td>Introduction</td>
<td>40</td>
</tr>
<tr>
<td>Leukopenia</td>
<td>40</td>
</tr>
<tr>
<td>Agranulocytosis</td>
<td>45</td>
</tr>
<tr>
<td>Hyperleukocytosis</td>
<td>55</td>
</tr>
<tr>
<td>Summary</td>
<td>56</td>
</tr>
<tr>
<td>Bibliography</td>
<td>1</td>
</tr>
</tbody>
</table>
INTRODUCTION

Five years have elapsed since Domagk (19) announced that he had found that prontosil had an elective action against experimental streptococcal infections in mice and rabbits. At the conclusion of this interesting report he says, "Prontosil zeigt eine bisher am infizierte Tier nicht beobachtete Streptokokkenwirkung. Es gelingt, streptokokken infizierte Mäuse, die unbehandelt innerhalb von 24 Stunden nach der Infektion eingelen, durch subcutane und perorale Prontosilsgaben am Leben zu erhalten. Prontosil zeigt eine elektive Wirkung bei der Streptokokkensepsis der Mäuse". In carrying out his experiments he observed that prontosil was not effective in vitro in preventing the growth or killing cultures of streptococci. He did not consider the drug toxic for he observed no signs of toxicity while he was testing the efficacy of the drug in combatting staphylococcal and streptococcal infections in laboratory animals.

His work was confirmed during the same year in France and later in 1935 Trefouel, Trefouel, Nitti, and Bovet (100) found that para-amino-benzene sulfonamide, the nucleus of the prontosils, was the active principle by demonstrating that it is effective in controlling
and curing experimental streptococcal infections in animals.

Interest in these new chemicals became actively stimulated on the continent and new chemicals with the para-amino-benzene sulfonamide nucleus were synthesized. More experimental work on experimentally infected animals was carried on, and the clinical use of the drug increased.

The medical professions both in America and England were apparently unaware of the fact that an important group of drugs had been found to have extraordinary power in curing both experimental and clinical streptococcal infections. This is explained by the fact that people naturally pay more attention to the journals written in their own tongue. In addition to this, the drugs were difficult to obtain in large enough quantities to carry on any significant work because American manufacturers had not yet perfected suitable methods of synthesis to make available cheap supplies of these drugs to investigators.

This unawareness, however, came to an end after Colebrook and Kenny (13) and Buttle, et al., (11) of England, and Long and Bliss (60) made their reports concerning the effects of this group of drugs in 1936. Since that time, the para-amino-benzene sulfonamide
(sulfanilamide) group of drugs has been very widely used for treating both clinical and experimental infections. Clinically and experimentally they have been employed for practically every known infection. It is no wonder that the statement is so often made that patients are first treated with sulfanilamide and if this has no effect upon the course of the illness a history of the illness is obtained and a physical examination of the patient is made to discover the nature of the patient's complaint. With such widespread use, both the beneficial and deleterious effects of these substances could be observed repeatedly.

These drugs have, without doubt, brought about a wonderful advance in the treatment of bacterial infections. In the case of such substances, it is relatively easy to become too enthusiastic over their effect and ascribe to them the properties of a cure-all. That these substances have been found to have toxic effects was not unanticipated since their nucleus is the benzene ring with an amino-group attached. Such drugs have long been known to be responsible for toxic effects upon the blood picture and hematopoietic tissue.

In comparing the incidence of serious toxic effects of the drug upon patients to those cases in which no serious toxic changes occur, it is apparent
that the percentage is small. Due to the fact that the drugs do have toxic effects should discourage their promiscuous use in conditions where there is no real indication for their use. Their use, however, should not be neglected in those cases in which it has been proved that they are curative and beneficial, e.g., streptococcal, meningococcal, gonococcal, and pneumococcal infections.

One of the most interesting toxic effects is the change which occurs in the blood picture of both animals and patients given these drugs. Our interest has been stimulated to some extent by the results obtained in a few animal experiments at the University of Nebraska (64) and also by the interesting reports of blood dyscrasias which have been increasing ever since the reports by Young (108) and Jennings and Southwell-Sander (46) have been published. In this thesis a brief review is being made of agranulocytosis and hemolytic anemia associated with the administration of the drugs of the para-amo-ino-benzene sulfonamide group.
When Plumer (77) reported in April, 1937, a death due to leucopenia following treatment of subacute bacterial endocarditis by sulfanilamide, the experimental production of blood changes produced by giving the drug to experimental animals had not yet been accomplished. Hawking (36) was unable to produce blood changes. Marshall, et al. (69) published their work concerning the toxicity of sulfanilamide in January 1938. They had fed 0.2 grams of sulfanilamide per kilogram to two dogs for two months and had not found any change in either the red cell, white blood cell, or in differential blood cell counts. Large doses of sulfanilamide were given to two dogs and four rabbits to determine whether sulfanilamide affected the blood count when given in large doses in a few days time. These doses ranged from 3.5 to 6 grams of the drug per kilogram in 2 to 5 days time. No effect upon the blood picture was observed. Hageman (33) gave 20 grams of sulfanilamide to a group of mice in 14 days time. Since he found that the spleens of these mice had much hemosiderin deposit and that the eosinophils of the bone marrow had increased, he suggested that the drug was able to destroy red blood cells and cause an allergic response.
of the bone marrow. Finkelstone and Sayliss (26) noticed abnormal erythrocytes and nucleated red blood cells in the blood of rabbits to which he fed 1.2 grams each day.

Domagk (19) was unable to produce any changes in the blood of experimental animals with prontosil and neo-prontosil. In 1937 he (20) found that sulfanilyl sulfanilamide and various derivations of that drug were able to cause various changes both in the white and blood cell picture. These changes were inconsistent as far as the white cells were concerned. The mono-methyl derivative of sulfanilyl sulfanilamide caused the red blood cell count to drop when given to laboratory animals. Bone marrow studies were not made to determine the reaction of the bone marrow to the drug.

Kreutzman and Carr (57) gave 8 rabbits doses of prontosil for a period of 21 days. The dosage was slightly higher than the recommended dose. The peripheral blood counts did not consistently change throughout the experiment but the red blood cell counts increased from 10 to 15% after the drug had been discontinued. Spleens were moderately congested and the single lobe eosinophils of the bone marrow were increased. These findings were interpreted to be suggestive of a mild bone marrow depression caused by the continued
administration of prontosil.

When Whitby (103) introduced sulfapyridine he thought that it would produce fewer toxic effects than sulfanilamide. Wien (104) gave 0.25 mgs. per gram of sulfapyridine to four rats for 14 days and 0.5 mgs. per gram to another group of four rats for 2 weeks. He used the same size dose of sulfanilamide for two other groups of rabbits for the same length of time. Two blood counts were made each week and no changes were found in the peripheral blood picture. No changes in the blood pictures were found in cats given 1 gram of sulfapyridine in 7 days or in dogs given an identical dose. When he fed larger doses of sulfanilamide and sulfapyridine, 1.5 to 3 mgs. per gram, to rats for 15 days, he found that those animals receiving sulfanilamide became anemic, had an increased amount of urinary porphyrin output, but those that had received sulfapyridine did not develop such changes.

During 1938 some of the effects of both small doses of sulfanilamide given over a period of five weeks and large doses given to rabbits were observed at the Nebraska University College of Medicine (64) 15 rabbits were given 4 grams of sulfanilamide per kilogram in a 24 hour period. At the end of the sixth day after the initial dose 13 rabbits were dead. The two
remaining rabbits were killed. The red and white blood cell counts showed no consistent change. The differential counts shifted to the left and the reticulocyte counts increased. Counts and studies made of the bone marrow stained by the panoptic stain revealed no significant alterations. Bone marrow counts of 8 normal rabbits were made in order to have a basis of comparison for the bone marrow counts made on the marrow from the experimental animals. In studying the chronic effects of sulfanilamide we made observations on two groups of rabbits. One group of four received daily doses of sulfanilamide, 1.0 gram per 9 kilograms of weight, for a period of 35 days. The other group, consisting of five rabbits, received the same dose, but each rabbit had a five-hour fever treatment each week throughout the course of the experiment. Studies of the peripheral blood throughout the experiment were made at weekly intervals and it was found that the small daily doses of the drug had no consistent effect upon the blood picture. Of the group of four, one animal died of pneumonia. The same dosage of sulfanilamide combined with fever did, however, result in blood changes in 3 rabbits. One rabbit was killed accidentally during the second week but no blood changes had developed at that time. Of this group the one rabbit
that was living at the close of five weeks had had no blood cell changes. The other 3 rabbits died 10, 15, and 24 days after the beginning of the experiment. Two of these rabbits had a leucopenia at the time of death with decrease in all the cellular elements. The other rabbit also had a leucopenia but the great reduction in the total count was due to the fact that only 2% of the cells were granulocytes. Unfortunately our bone marrow preparations were unsatisfactory.

During 1939, several interesting reports concerning the effects of drugs of the para-amino-benzene sulfonamide group were made. Rosenthal (86) and Nelson (73) studied the effects and histopathological changes in hens and rabbits following administration of sulfanilamide and sulfapyril sulfanilamide to rabbits and chickens. They found that these drugs both have cumulative toxic effects for both rabbits and hens. Bone marrow from 11 rabbits that had received repeated doses of sulfanilamide were examined. Of 11 preparations studied, 3 were normal, 3 slightly hypoplastic and 5 were moderately hyperplastic. In 3 of the hyperplastic bone marrows the proportion of early forms of cells to late forms was normal. One hyperplastic tissue was found to contain increased numbers of stem cells and early granulocytic forms and the fifth of this group of hyperplastic
marrows showed that an increase in the mature forms of granulocytes had occurred. It was found that one of the hypoplastic tissues had a reduction in the number of normoblasts. The bone marrow of rabbits treated with disulfanilamide had less pronounced changes occur after the drug had been administered in repeated doses. Of 9 bone marrows studied, 6 were normal. Of the three which were abnormal, one had a hypoplasia of granulocytes, one a hypoplasia of normoblasts, and one bone marrow preparation had a hyperplasia of immature granulocytes. All the bone marrow studies made on the hen bone marrow given either sulphanilamide or disulfanilamide in repeated doses showed hypoplasia.

Later in 1939 Rosenthal and Bauer (87) were able to demonstrate hydroxylamine derivatives in the urine of rats, rabbits, dogs, and man after they had had sulfanilamide administered to them. This was found in larger quantities in the urine of man and rabbit than in the other animals. These oxidation products were found to be of greater toxicity than the original drug administrated.

Holitor and Robinson (72) in 1939 published the results of their study of acute, cumulative and chronic toxicity as well as pharmacological effects of
sulfanilamide and benzyl sulfanilamide upon 1000 animals. 
Dogs to which they gave sulfanilamide for 3 week periods 
had no blood picture changes. In every case they observed 
that sulfanilamide was very much more toxic than benzyl 
sulfanilamide. They had no deaths of animals fed as 
much as 45 grams per kilogram for 10 days. Pathological 
changes they found in the tissues of animals which are 
significant were large, hyperemic, pigmented spleens. 
The pigment was both iron and non-iron containing 
substances. The bone marrow was moderately hyperplastic. 
Pigment was also present in the lymph glands and in the 
convoluted tubules of the kidneys. These findings indi­
cated that a destruction of blood elements occurred 
which was responsible for increased stimulation of 
bone marrow.

That sulfapyridine is harmless and non-toxic 
for mice was concluded by Johannsen (47) during his 
investigation of the toxic and therapeutic effects of 
the drug. This is not the same conclusion which 
Holitor and Robinson as well as Antopol and Robinson (3) 
reached during their experiments with sulfapyridine with 
various kinds of laboratory animals. Bone marrow hyper­
plasia of the myelogenous elements as well as lymphoid 
hyperplasia and pigmentation of the spleen was found. 
Peripheral blood studies were not made in these
Very interesting is the work reported by Eiggins and Machella.\( (37) \) They induced anemia in rats in a period of 10 days to two weeks by using doses of 1 gram of sulfanilamide to 1 kilogram of weight. They attributed the anemia due to a direct effect the sulfanilamide has upon the blood cells of the rat. They found coproporphyrin in the urine of rats and say that its presence indicates a bone marrow derangement. When they gave rats the same dose of sulfanilamide in connection with five 50 mg. doses of nicotinic acid, anemia developed as it had when the drug was administered without the nicotinic acid. Bone marrow studies were made. No impaired hemopoiesis was found. There was some erythroid shift but the essential structure of the bone marrow was not impaired.

Machella and Higgins \( (65) \) have been able to induce anemia in rats by administering doses of varying quantity to different groups. Their work is especially interesting since very similar cases have been reported as a result of the therapeutic use of the drug in treating infections in man. The experiment and its results are described briefly. They used four different doses of sulfanilamide on each of four different groups of
rabbits. For convenience, a list of the dosage and groups is included.

<table>
<thead>
<tr>
<th>Dosage</th>
<th>No. of Rats in Group</th>
</tr>
</thead>
<tbody>
<tr>
<td>0.25 gms. per Kg.</td>
<td>6 rats</td>
</tr>
<tr>
<td>0.5 gms. per Kg.</td>
<td>6 rats</td>
</tr>
<tr>
<td>1.0 gms. per Kg.</td>
<td>12 rats</td>
</tr>
<tr>
<td>2.0 gms. per Kg.</td>
<td>12 rats</td>
</tr>
</tbody>
</table>

They were able to induce anemia in these rats in which the degree and rapidity of onset were dependent upon the size of the dose given. A list of the results they obtained is included.

1. Increased color index.
2. Anisocytosis and macrocytosis.
3. Rapid decrease in red blood cell count and hemoglobin. Degree and rapidity of drop dependent on the size of the dose.
4. Rats were thirsty, cyanotic, drowsy and irritable during the onset and throughout the course of the drug administration after changes had begun.
5. Initial drop in white blood cells was followed by leukocytosis.
6. Steady and progressive drop in the total hemoglobin also was observed.
7. In the bone marrow, the erythroid and myeloid cells were increased. A transient increase in eosinophilic metamyelocytes was also noted.

8. Examination of tissues was made. Findings were hemorrhagic gastritis, black spleens enlarged lymph glands, and dark livers. These animals had a gradual recovery from the anemia after the drug was discontinued.

In summarizing the work of the effects of various sulfonamide drugs upon the blood cells and hemopoietic systems it is concluded that these drugs do affect the blood cells and the hemapoietic tissues. The presence of increased amounts of pigment in the spleen and in some cases in other tissues of the body indicates that an increased amount of red blood cell destruction occurs when these drugs are administered. That the red cell count and hemoglobin does actually decrease was indicated by Mackella's and Higgins' (37)(65) work. There is little work showing changes in the peripheral white blood cell counts since most of the work of investigation of the harmful effects of these drugs on experimental animals did not include blood counts. Since the bone marrow did have an altered picture in most instances, it is reasonable to conclude that had the peripheral blood picture been studied, the
changes found during histopathological studies of the bone marrow would have been reflected by the peripheral blood.
AGRANULOCYTOSIS AND HEMOLYTIC ANEMIA: SENSITIVITY REACTIONS OF THE BONE MARROW.

Introduction

Since 1937 the number of reported cases of hemolytic anemia and agranulocytosis associated with or following therapy with sulfanilamide and allied compounds has increased. That this should occur is natural since the total number of patients treated constantly increases and provides opportunity for more blood disturbances to develop. Undoubtedly the few observations of blood changes associated with these drugs in animal work is due to the fact that the course of the effect of the drug has not been so closely watched as in human beings treated with the substances, nor have as many animals been exposed to the drugs as human beings.

Hemolytic Anemia

Before considering the red blood cell and white blood cell disturbances following the use of the sulfonamide drugs, a brief review of the nature or character of the conditions known as hemolytic anemia and agranulocytosis is given.

Hemolytic anemia is a condition characterized by hyperbilirubinemia, urobilinuria, hemosiderosis,
reticulocytosis and normoblastic hyperplasia of the bone marrow, and a high grade of leukocytosis if large numbers of red blood cells are suddenly destroyed.

It may be due to peripheral hemolysis caused by a direct hemolytic effect of certain chemicals, bacterial toxins, and drugs or due to an idiosyncratic effect caused by complex antigen-antibody reactions of foreign proteins or various chemical compounds. (27) Examples of direct hemolytic poisons are phenylhydrazine, trinitrotoluene, hydrogen arsenide, n-propyl disulfide, snake venoms, saponins, and bacterial toxins. Fitzhugh (27) says that the hemolytic effect of dinitrophenol, acetanilid, and antipyrine is due to an individual idiosyncrasy of an occasional person, for these substances do not cause a hemolytic anemia in the larger percentage of people to whom the drug has been given. Since the advent of sulfanilamide, both Long (60)(61)(62)(63) and Fitzhugh (27) think that the hemolytic anemia which develops during sulfanilamide therapy is a manifestation of an anaphylactic or idiosyncratic effect which the drug has on an occasional patient.

It is admitted that hemolytic anemia is due to complex sensitivity reactions but the factors which are concerned in the actual production of an occasional
sensitivity are not known. This is true not only for this type of allergy but for all allergic phenomena. Factors to be considered are heredity, hormonal mechanisms, dysfunction of liver and spleen, fatigue states, traumatic shock, toxemias which include putrefactive disturbances and various bacterial and protozoan infections, deficiency states. Radiation effects, also are to be considered. Fitzhugh (27), Jackson and Parker (43), Kracke and Parker (55), Madison and Squier (66), Pepper (76), and Rosenthal (84) all feel that these factors are to be considered as etiological agents in the production of various sensitivity reactions of the blood and bone marrow.

Agranulocytosis

Introduction. In 1922 Schultz (90) reported a condition which he named agranulocytosis. The disease he described was characterized by an acute onset, with chills, fever, jaundice, ulcerative and gangrenous lesions in the mouth, and leucopenia with granulocytopenia. All of the six cases which he reported occurred in middle-aged women who had been in good health. The six cases were all fatal. According to most workers who have investigated and observed agranulocytosis since that time, this is regarded as a new disease. (27)(22) (23)(45)(55)(66) Pepper(76), however, thinks that the
condition, formerly known as putrid sore throat, was an analogous condition. The other workers feel that since blood counts have been done for over 50 years, certainly the disease would have been reported before 1922 had it actually existed.

**Definition.** Before the discussion of agranulocytosis or agranulocytic angina is continued, the condition should be defined. At first in glancing through the literature one is confused by the large number of different terms used to name the symptom complex. The expressions acute granulocytic angina, agranulocytosis, malignant granulopenia, and acute primary granulocytopenia are synonymous terms according to Jackson and Tighe. (44) Kracke (53) says that the term agranulocytosis, strictly speaking, is a misnomer for it means an increased number of immature granular cells. Fitzhugh (27) suggests the term pernicious granulocytopenia. For the purpose of avoiding confusion in this discussion, the term agranulocytosis is being used, and the condition is defined as an acute disease characterized by extreme leukopenia and granulopenia and systemic reactions which in turn may be followed either by no infection, localized infection, or generalized infection.
Etiology. The exact etiology is unknown. There are, however, predisposing etiological factors. Pepper (76) has observed that there is a higher incidence of this disease among allergic patients than in non-allergic people. Kracke (54) is well known for his work both in the clinical investigation of the disease as well as the experimental production of the condition by various substances such as benzene, hydroquinone, and ortho-oxybenzoic acid. He says it is a disease of the myeloblastic tissues followed by a loss of resistance, resulting in overwhelming infection, but the exact etiological agent is not known. Madison and Squier (66) were able to cause a fatal agranulocytosis in 1 of a group of 11 rabbits, by benzene drugs and feel that these drugs are in some manner responsible for a sensitization of the bone marrow which results in sudden leucocyte decrease. That drugs are responsible for the condition, especially those of the benzamine group, is the most tempting of theories, but at times cases of agranulocytosis develop when there is no history of the use of drugs of this group. Kracke (55) quotes the work of Plum who made a very extensive survey of the incidence of agranulocytosis in Denmark. He was able to correlate the incidence of agranulocytosis with the incidence of use of aminopyrine. The greatest
incidence of the disease occurred during 1933 and 1934 when the largest amount of the drug was being consumed in Denmark. This was well demonstrated by a graph he constructed in which it was demonstrated that the curve representing the use of aminopyrine and that representing the incidence of agranulocytosis were parallel.

Another interesting fact regarding the incidence and distribution of agranulocytosis is that 90% of the cases occur in the United States and Germany. (44)(53)(55)(76) This corresponds to the area in which aminopyrine was most frequently used a few years ago. By the time sulfanilamide became a popular therapeutic drug, the incidence of agranulocytosis had decreased greatly associated with the lessened use of aminopyrine. It is as yet too early to measure the effects that the introduction of this new product will have upon the total incidence but, judging by the increasing number of reports of agranulocytosis associated with therapy with this group of drugs, it is very likely that the incidence has made a very definite increase.

The hormonal factor as an etiological factor in the production of agranulocytosis is suspected to play a role because the condition occurs most often between the ages of 30 and 40. The ratio of the
incidence occurring in women and men is 3 to 1, the greatest percentage being found in women.

That the standard of living has an effect is well borne out by the fact that before sulfanilamide was introduced, the occurrence of agranulocytosis was most common in that class of people of higher economic standards. Of this group nurses, physicians, and members of the family of physicians were found to have the disease most frequently.

When Schultz described agranulocytosis he said that the cause was due to an acquired sensitivity of the leukocytes, endothelium, and leukopoietic tissues to certain drugs or other allergens. Despite much observation and investigation since that time, little more can be said in regard to the disease today. If it is a bone marrow idiosyncrasy, does it result in a lack of a maturation factor or a lack of a chemotactic factor which interferes with the delivery of the blood cells into the vascular system? Fitzhugh calls the condition pernicious granulocytopenia for he believes that the condition is caused by an arrest in the maturation of granulocytes which is analogous to the arrest of maturation of erythrocytes in pernicious anemia. He believes this to be true because he has been unable to find a decrease in the myeloid cells of the
bone marrow, but has found a hyperplasia of the early forms of granulocytes. Furthermore, the lesion of the leukopoietic tissues is reversible to a certain point if it has not continued so long that aplasia finally results. Remissions of the disease are characterized by an outpouring of young cells before the mature forms appear. Fitzhugh has said that possibly the sudden onset is due to the fact that the inciting factor may cause the cells to stick to the endothelial lining and thereby cause a sudden marked drop in the cell count. That no evidence of abnormal distribution of granulocytes is found during histopathological studies is explained by the fact that the adherent cells disintegrate rapidly.

Overwhelming septic conditions do occasionally result in a profound as well as fatal leukopenia associated with a profound reduction of the granulocytic cells. It is the opinion of Kracke (53)(54), Pepper (76), Jackson (43)(44), Madison and Squier (66), and Fitzhugh (27) that the sepsis which is often associated with agranulocytosis is not the actual cause but rather the result of agranulocytosis which depletes the resistance of the tissues to infection by the lack of defensive agents. Domagk (21), however, does not believe that true agranulocytosis develops as a result of the
administration of the amino-benzene sulfonamide compounds but that the granulocytopenia is the result of the effect of the etiological agent producing the disease for which the drug is being used. That a granulocytopenia can develop in response to a severe infection is true. Schilling (89) says that this is either brought about by the overwhelming irritation of a severe acute sepsis or persistent drain of a long continued infection. In the case of sulfanilamide, however, it is hardly possible to believe that the infections have been so much more severe during the past few years that the infection itself and not the sulfonamide drugs have been responsible for the increased number of reports of agranulocytosis. In this connection the case reported by Ives (42) is very interesting. A negro patient after nine days of illness with hemolytic streptococcic angina had a total white blood cell count of 9000 with a complete absence of granulocytes. The patient had a grayish black necrotic membrane over his pharynx, he was confused, drowsy, and complained of a headache and joint pain. The lowest white count was 1200, with no granulocytes one day after hospital admission. 5 cc. of prontosil every four hours and 60 grains of sulfanilamide as well as intramuscular liver extract and intravenous pentnucleotide were
administered as soon as the blood findings were made. Recovery began on the second day after beginning of therapy and the patient had an uneventful course of illness in the hospital. In this case the sepsis was overwhelming enough to cause a severe granulocytopenia, and the drug was indicated because the toxic, septic process had to be controlled.

**Pathology.** The pathological changes of agranulocytosis are located chiefly in the bone marrow. If angina occurs, necrosis and ulceration without evidence of granulocytic invasion occur in the mucous membranes, chiefly those of the tongue, nasopharynx, and pharynx. Necrotic lesions are occasionally found in the vagina, gastro-intestinal tract, and bladder.

The bone marrow changes are the most important pathological findings of this disease. Kracke (53), Jackson (44)(43), Fitzhugh and Krumbhaar (28), and Darling, et al., (22) find that there is a maturation arrest with hyperplasia at the stem cell stage of the myeloid elements of the bone marrow if the disease is rapidly fatal. If the disease is prolonged there is an increased number of plasma cells and lymphocytes with hypoplasia of the myeloid cells. There is, however, no evidence of degenerative changes occurring in the bone marrow cells. If the bone marrow
is degenerated it is either the result of an infection or poor fixation of the tissue. Bone marrow from patients who are recovering from the infection has increased numbers of more mature cells. Rosenthal (35) finds that the bone marrow is aplastic. Pepper (76) also believes that an aplastic as well as a degenerated bone marrow is found in these conditions. It is possible, as Jackson (44) says, to misinterpret bone marrow findings, especially if the tissues have been improperly fixed. It is also possible that Pepper (76) and Rosenthal (35) both examined bone marrow from patients with a prolonged course of the disease. Jackson (44) also thinks that the original report of the bone marrow findings by Schultz (90) are also frequently misinterpreted to mean aplasia of the bone marrow instead of a maturation arrest. To us it seems that the conclusion may be reached after having examined the reports of the various authorities that the bone marrow may be either aplastic, hyperplastic, or hypoplastic.

Course of Disease. Clinically, the course of the disease has an acute onset. Often there is a prodromal period of malaise. The fever is high, ranging from 104° to 107° F. The patient is prostrated, usually complains of severe headache, has chills and a sore throat. Often there are ulcerative lesions both in the nose, mouth
and throat which have a peculiar gray green appearance with very little or no inflammatory change. The breath is foul. Along with these findings and symptoms there is extreme leukopenia with a great reduction in granulocytes. Often no granulocytes are found in the peripheral blood and the total count may be as low as only a few hundred cells. A few reports told of counts less than 100 white blood cells per cubic millimeter. Often positive cultures are obtained from the blood, but the bacteria are not regarded as the etiological agents of agranulocytosis, but the result of invasion of the body tissues as a result of the absence of the defense barrier which the granulocytes provide in protecting the body against bacterial infection. The disease has a rapid course and may terminate fatally in from 2 to 6 days or recovery when it occurs is complete in 2 weeks. Jackson (44) reports a 78% mortality. Kracke (53) found that 85% of 250 patients afflicted with agranulocytosis died. Madison and Squier (66) observed 14 cases following aminopyrine injection. Of this group 8 died. It is uncertain what the exact mortality rate is, but there is no doubt that it is high.

**Diagnosis.** Diagnosis is based upon the following findings: Hemorrhage does not occur, few
immature white blood cells are present in the blood at the height of the disease, neither the liver nor the spleen are enlarged, and lymphadenopathy does not occur except that explained by local areas of sepsis. In addition to these findings recovery, if it occurs, is complete in two weeks, relapses are uncommon. Usually careful questioning and investigation will elicit the fact that some form of a benzene or aminobenzene drug has been used. Bone marrow changes may be an aid to diagnosis, but if we go on the assumption that it may be aplastic, hyperplastic or hypoplastic, it is necessary to correlate all the findings to arrive at a definite diagnosis.

Differential diagnosis may be very difficult. (44)(45) Other conditions from which it must be differentiated are overwhelming infections; benzol, gold, bismuth and arsenic poisoning; acute leukemia; aplastic anemia; and acute infections such as typhus, measles, mumps, influenza, malaria, dengue fever and roseola which characteristically have low total white counts. Careful blood studies, thorough examination, and complete histories are all valuable aids in establishing a diagnosis. An aplastic bone marrow with blood findings indicating a severe anemia, thrombopenia, and neutropenia is typical of aplastic anemia. If there is
a history of administration of gold, arsenic, bismuth, or benzol before the onset of such findings the etiology of the aplastic anemia is established.

Acute infections (53) seldom cause much diagnostic difficulty because of characteristic signs and symptoms which do not harmonize with the blood dyscrasias. Both acute leukemia as well as a neutropenia due to an overwhelming sepsis may be very difficult to differentiate from agranulocytosis. The neutropenia associated with sepsis is termed agranulocytic sepsis by Kracke. (53) This condition may follow surgical procedures (81)(102) as well as acute infections (42)(9) and it may be very difficult to determine whether the symptoms and findings are pathognomonic of an idiopathic agranulocytosis or of an exhaustion or intoxication caused by the septic process. A bone marrow study may give the only clue by degenerative and toxic changes found within the cells. Severe septic processes of this type are apt to have an associated secondary anemia which may also be helpful in establishing the true diagnosis.

Jackson (45) warns of the ease in which acute leukemia and agranulocytosis may be confused. Only careful study of the patient's hematological picture correlated with the physical findings will, in some cases result in a definite diagnosis of either one of these
HEMOlyTIC ANEMIA ASSOCIATED WITH SULFANILAMIDE
AND RELATED COMPOUNDS

Introduction

Both mild, slowly progressive hemolytic anemia and acute hemolytic anemia with a sudden drop in hemoglobin and red cells are associated with the administration of sulfanilamide and sulfapyridine.

Progressive Hemolytic Anemia

Long (63)(59)(61) and Wood (106) as well as Garvin (30) have all observed that a progressive hemolytic anemia with a fall of from 10% to 20% hemoglobin occurs in some patients. Jennings and Southwell-Sanders (46) made the first report of a slowly progressing hemolytic anemia associated with sulfanilamide administration. This is most often noticed in those patients who have received the drug for several weeks and most often appears after the tenth day. The reticulocyte count increases and there may or may not be a slight urobilinuria. All of these three workers make their statements after having observed many patients, but they do not state the percentage of patients treated over a long period of time that developed the low grade, chronic hemolytic anemia.

Incidence. Bigler, Clifton, and Werner (7)
studied the blood picture of 33 patients while receiving sulfanilamide. They observed no severe anemia, nor did they find that any of their patients developed a low grade anemia. In fact, they say that often the hemoglobin of their patients apparently increased. Counts were done two times each week during a period of 28 days on 50 ambulatory patients being treated by sulfanilamide by Britton and Cowkins.(10) The dosage prescribed was 0.5 gram three times a day for 14 days. During that time they detected no evidence of a hemoglobin or red cell decrease. Hageman (32)(34) in reviewing 114 cases treated with sulfanilamide found one case of hemolytic anemia. Campbell (12) observed the blood picture of 10 cases being treated with sulfanilamide. Anemia was not found but the reticulocyte count increased. It is possible that destruction of the red blood cells did occur, but it was so slight that anemia was not detectable because the bone marrow was able to replace red cells as fast as they were destroyed.

Long, Bliss, and Feinstone (63) have observed that chronic anemia may also result when sulfapyridine is used. Hodes, et al., (39) studied 71 cases of pneumococcic pneumonia treated with sulfapyridine and found no significant hemoglobin change. Barnett, et al., (5) report no anemia from sulfapyridine therapy in a
group of 23 cases. No anemia is reported by Evans, et al., (25) who used sulfapyridine to treat pneumonia. Rosenthal and Vogel (84) who use the same drug have found that hemolytic anemia does occur.

Discussion. This type of anemia is not regarded as a grave complication of sulfanilamide therapy. Long and Bliss (59)(61)(62)(63) do not regard this complication of severe enough consequence to discontinue the drug unless the hemoglobin has dropped below 60%. The blood regenerates quickly if the drug is stopped and if the infection is not yet controlled and the hemoglobin has dropped to the 60% level they advise continuation of the drug with a blood transfusion.

Acute Hemolytic Anemia

The acute hemolytic anemia which develops is both spectacular and serious. Harvey and Janeway (38) made the first report of this toxic effect of sulfanilamide. The early symptoms, before the anemia develops, are nausea; dizziness; increased urobilin; fever; and symptoms of toxicity.(106)(30)(61) Other findings reported by these workers, as well as those whose cases are tabulated in Table I, are a rapid, and pronounced fall in the hemoglobin and the number of red blood cells. The count may drop as much as
<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex</th>
<th>Age</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Diagn</th>
</tr>
</thead>
<tbody>
<tr>
<td>Antopal</td>
<td>Male</td>
<td>34</td>
<td>8 gms. Prontosil</td>
<td>3</td>
<td>Pneum</td>
</tr>
<tr>
<td>Applebaum Goldman</td>
<td>Female</td>
<td>64</td>
<td>24 gms. Sulfan.</td>
<td>4</td>
<td>Mastc</td>
</tr>
<tr>
<td>Rosenthal Vogel</td>
<td>Male</td>
<td>9</td>
<td>9 gms. Sulfapy.</td>
<td>3</td>
<td>-</td>
</tr>
<tr>
<td>Wood *</td>
<td>Male</td>
<td>28</td>
<td>41/4,66 gms. Sulfan.</td>
<td>6</td>
<td>Stre</td>
</tr>
</tbody>
</table>

* Bone marrow was very hyperplastic w/ proliferation.
<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex</th>
<th>Total Age</th>
<th>Drug</th>
<th>Total Days</th>
<th>Diagnosis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wood(106)</td>
<td>Male</td>
<td>36</td>
<td>Sulfan.</td>
<td>5</td>
<td>Tonsil</td>
</tr>
<tr>
<td></td>
<td>Same Pt.</td>
<td>1 Yr. later</td>
<td>Sulfan.</td>
<td>3</td>
<td>Tonsil</td>
</tr>
<tr>
<td>Rosenblum</td>
<td>Male</td>
<td>2 gms.</td>
<td>Sulfan.</td>
<td>2</td>
<td>Tonsil</td>
</tr>
<tr>
<td>Rosenblum</td>
<td>Male</td>
<td>2 gms.</td>
<td>Sulfan.</td>
<td>2</td>
<td>Tonsil</td>
</tr>
<tr>
<td>Nelson Scott-</td>
<td>Female</td>
<td>48 gms.</td>
<td>Sulfan.</td>
<td>23</td>
<td>Gonorrhea</td>
</tr>
<tr>
<td>Young</td>
<td>32</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvey Janeway</td>
<td>Male</td>
<td>22.8 gms.</td>
<td>Sulfan.</td>
<td>5</td>
<td>Sore Th</td>
</tr>
</tbody>
</table>
TABLE I (Con't)

Tabulation of Cases of Hemolytic Anemia Due to Drugs of the Para-Amino-Benzene-Sulfonamide Group

<table>
<thead>
<tr>
<th>Reference</th>
<th>Sex</th>
<th>Age</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Diagnosis</th>
<th>Lowest Hb.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Harvey Janeway</td>
<td>Female</td>
<td>26</td>
<td>12.2 gms.</td>
<td>2</td>
<td>Peritonsillar Abscess</td>
<td>18%</td>
<td>2 Blood Transfs.</td>
<td>Recovered</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td>Dev.in 36 hrs</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Harvey Janeway</td>
<td>Female</td>
<td>10 mos.</td>
<td>8.92 gms.</td>
<td>7</td>
<td>Meningitis</td>
<td></td>
<td>2 Blood Transfs.</td>
<td>Recovered</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td>Dev.in 7 days</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kohn</td>
<td>Female</td>
<td>1 Yr.</td>
<td>6 gms.</td>
<td>6</td>
<td>Ot.Media</td>
<td>6.0 gms.</td>
<td>Intramus. Blood</td>
<td>Recovered</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td>2,000,000</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Jennings Southwell-Sander</td>
<td>Male</td>
<td>45</td>
<td>30 gms. sulfan.</td>
<td>8</td>
<td>Meningitis</td>
<td>50%</td>
<td>Iron Transf.</td>
<td>Recovered</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td>6 gms. pront. flav.</td>
<td></td>
<td>Meningitis</td>
<td>2,500,000</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
two million in 24 hours. Marked reticulocytosis, leukocytosis, bilirubinemia, urobilinuria, porphyrinuria, jaundice, and occasionally jaundice are also associated with this condition.

In considering predisposing factors, it was found that no one type of infection was associated with the acute anemia. The size of the dose and the concentration of the drug in the blood do not seem to be factors for both high and low values were associated with the syndrome. The carbon dioxide combining power in 19 of Wood's (106) 21 cases of acute hemolytic anemia cases was within normal limits. Table II is a table taken from a report by Wood (106) demonstrating a hypersensitivity of the red blood cell system to sulfanilamide after the four patients had recovered from a previous attack of acute hemolytic anemia. Case A.D. is a case cited by Willis. (105) All of the patients had fever.

Incidence. Acute hemolytic anemia is not more prevalent in one sex than in the other. It is, however, more prevalent in children than adults. Wood(106) has observed 522 patients treated with sulfanilamide. Of this group 144 were children and 378 were adults. A total of 21 cases of acute hemolytic anemia occurred in the children's group and 9 in the adult group, or 8.37% and 2.4% respectively. No large group of patients
Table from Wood (106) Summarizing Five Anemia Occurrences Following a Second Course

<table>
<thead>
<tr>
<th>Patient</th>
<th>Sex</th>
<th>Age</th>
<th>Diagnosis</th>
<th>Days of Treatment</th>
<th>Total Dose</th>
<th>Dr %</th>
</tr>
</thead>
<tbody>
<tr>
<td>No.1</td>
<td>Male</td>
<td>36</td>
<td>Acute Tonsillitis</td>
<td>5</td>
<td>21.9</td>
<td></td>
</tr>
<tr>
<td>No.2</td>
<td>Male</td>
<td>4 days</td>
<td>Ophthal. Neo.</td>
<td>1/4</td>
<td>7.4</td>
<td></td>
</tr>
<tr>
<td>No.3</td>
<td>Male</td>
<td>2</td>
<td>Pulmon. Tb.</td>
<td>7</td>
<td>1/4.0</td>
<td></td>
</tr>
<tr>
<td>No.4</td>
<td>Female</td>
<td>7 Mos.</td>
<td>Otitis Media</td>
<td>3</td>
<td>4.5</td>
<td></td>
</tr>
<tr>
<td>No.5</td>
<td>Female</td>
<td>9 Mos.</td>
<td>Pyelitis</td>
<td>3</td>
<td>5.8</td>
<td></td>
</tr>
</tbody>
</table>
treated with sulfapyridine has as yet been reported. Hemolytic anemia, however, also occurs in patients treated with sulfapyridine. (29)(84) No hemolytic anemia associated with either prontosil or disulfanilamide has been reported but 2 cases treated with diamino diphenyl sulfone are reported. (62)

**Course and Prognosis.** The onset of the disease is from 24 to 72 hours after the beginning of the drug administration. The maximum anemia occurs from the third to seventh day, most often on the fifth day.

The mortality rate is low because the condition responds well to withdrawal of the drug and blood transfusions. Two fatal cases are reported, one by Wood (107) and the other by Koletsky. (52) (See Table I.) The case reported by Koletsky died 6 days after the beginning of the first dose of sulfanilamide and 2 days after the drug was discontinued. No transfusions were available. The death following the development of anemia reported by Wood (107) is evidently due to the fact that transfusions were started too late in the course of the disease. The drug had been discontinued on the sixth day but no transfusion was given until the twelfth day. The patient died on the sixteenth day after the drug had first been started.
Possible Mechanism. That the acute hemolytic anemia, which develops during the course of therapy with several drugs of the sulfonamide group, is due to an individual idiosyncrasy is very evident. That the condition does not occur in every case is one proof of this and the fact that 3 out of 4 patients have a recurrence of the symptoms when the drug is repeated is evidence that these patients are hypersensitive to the drug.(63) As with all idiosyncrasies, the mechanism by which it works is not understood. There is no bone marrow depression as is indicated both by the reticulocytosis and leukocytosis as well as by bone marrow studies that reveal a hyperplasia of both erythroid and myeloid elements. The drug does not hemlyze the red blood cells of these patients, nor are the cells of these patients more easily hemolyzed by hypotonic saline than in normal patients. (53)(106)(107) Histopathological study of other tissues, besides the bone marrow, reveals changes typical of any severe hemolytic anemia. The most typical finding is hemosiderin deposits in the tissue. So the pathology gives no clue to the mechanism of the anemia production. Both Long (63) and Wood (106) report the presence of porphyrin in the urine. Rimington (82) has found that porphyrin increases when sulfanilamide is given to patients. He believes that the porphyrin
production is not related to the bilirubinemia associated with red cell destruction, but he thinks it is produced because the sulfanilamide may possibly be responsible for a disturbance in pigment metabolism with a deep-seated effect upon the hemapoietic system. He says that hemoglobin forms bilirubin without passing through a porphyrin stage. It is necessary to conclude that the mechanism of the production of hemolytic anemia by drugs of this group is not understood.

**Treatment.** Treatment of hemolytic anemia is simple. Two main conditions must be fulfilled. In the first place, the drug responsible for the idiosyncrasy must be eliminated. This is accomplished by forcing fluids and discontinuing the drug. These drugs are excreted almost entirely by the kidney (68)(75) so water diuresis is very necessary. In the second place blood transfusions are necessary not only to tide the person over the critical period until the bone marrow is able to regenerate blood cells to replace those destroyed but also to prevent irreparable tissue damage in case of profound anemia. Many of these patients become so anemic that cyanosis is not present even though a considerable portion of the remaining hemoglobin has been changed to methemoglobin.(78) Furthermore, it is possible for toxic effects to manifest themselves from 3 to 4 days
after the last dose (18), and it seems too great a risk to take a chance and hope that the hemoglobin and red cells will not drop farther even though the drug has been discontinued. That these methods are satisfactory in preventing mortality is indicated by reports of Long (63), Wood (106) (93) (38) (74). Occasionally (63) if the infection is very severe and there is no control of it yet established when the anemia occurs, it is justifiable to continue the drug therapy provided the patient is carefully watched and repeated daily transfusions are given to control the anemia.
LEUKOPENIA AND AGRANULOCYTOSIS ASSOCIATED WITH SULFANILAMIDE AND RELATED COMPOUNDS.

Introduction

The literature concerning disturbances of the white blood cells due to the benzene-sulfonamide drugs is very much greater in amount than that relating of red blood cell disorders. Undoubtedly this is due to the fact that agranulocytosis is a very severe and often fatal complication following not only the para-amino-benzene sulfonamide group but also the benzene drugs, especially the benzamines, to which the group under discussion belongs.\(^{(56)}\)

Agranulocytosis is, however, not the only disturbance of white blood cells encountered when the effects of these drugs on the leukocytes are reviewed. Other conditions are leukopenia and hyperleukocytosis.

Leukopenia

Trumper in 1937 \(^{(77)}\) in a letter addressed to the New England Journal of Medicine said that two cases which he had been treating with prontosil and prontolyn had had marked reductions in the total white count. One patient with a septic mastoid had dropped from 18,800 white blood cells to 4,000 with 35\% granulocytes. The white count in the other patient suffering
from puerperal sepsis dropped from 20,000 white blood cells to 5,000 with 50%-60% granulocytes. This seems to be the first report which appeared in the literature which indicated that sulfanilamide and prontosil may affect the blood picture in some manner. In both instances the white cell count rose when the drug was discontinued.

Some believe that the derivatives of sulfanilamide as well as that drug itself have a depressive effect upon the white blood cells. This is the opinion of Bigler (7) who studied the leukocyte response of 33 patients to sulfanilamide therapy. Since they observed the number of leukocytes became less during the course of treatment, they concluded that the cell drop was an effect upon the cells and not a natural result of the termination or recovery from the original infection. That they made that conclusion seems especially strange when it is found during examination of their reports that no one type of cell was decreased out of proportion to the other cells. Although they did find that in three instances the total count was slightly below 5000, no evidence of granulocytopenia is present.

Britton (10) observed a group of 50 ambulatory patients who received the drug for two weeks, but whose blood counts were done 2 times a week, both during the
treatment and the following two weeks. Of this group 32 had no marked variations in white cell counts. In 14 cases the count dropped to between 5000 and 4000 and 4 cases had white cell counts that dropped below 3000. At the beginning none of the patients had either a leukocytosis or leukopenia. Blood counts were done on 17 untreated normal controls during the same period.

The types of cases being treated consisted of cervical erosions, urinary infections, gonorrhea, and one case of syphilis. Of their 14 cases whose count fell to between 5000 and 4000, 2 cases were lowest during the first week, 3 cases lowest during the second week, and 9 cases were lowest during the third week, that is, the first week after the medication had been discontinued. Those 4 cases in which the white cell counts dropped below 4000, had that occur during the third week. In only five of their cases was a true neutropenia observed where the granulocyte count dropped below 2000.

After analyzing their findings, they found that there was a tendency for the average total white cell count to drop during the first week and remain low for the following two weeks with a rise to normal occurring at the end of the third week.

Two hundred and fifty cases treated with sulfapyridine were summarized by Lloyd, et al. (58).
They say that a small proportion of these patients had slight but definite decrease of the leukocyte count associated with a neutropenia and relative lymphocytosis. They observed no dangerous depression of the granulocytes and say that the white count quickly rose to normal levels with discontinuation of the drug.

Hodes, et al., (39) treated 71 cases of pneumonia with sulfapyridine. He reports 5 cases of mild granulocytopenia and one case of severe granulocytopenia which all recovered as soon as the drug was discontinued. Flippin (29) reports one case of leukopenia in a group of 100 cases treated with sulfanilamide.

From the reports of the results of sulfapyridine therapy it is apparent that a depression of leukocytes is associated with the administration of this drug. That the drug is an etiological factor concerned in the cell depression is evident since the count returns to normal after it has been discontinued. Whether these decreases in the total white count are in the nature of a mild hypersensitivity reaction or due to a direct toxic effect upon the white blood cells or marrow, we have no way of knowing. That either one of the two conditions may exist is possible. In every case the condition was mild and no other toxic symptoms were associated with the change in the blood picture.
In the 408 cases observed by Long (62)(63), no mild or transient cases of leukopenia associated with granulocytopenia are noted. The only white blood cell disturbances encountered was one case of agranulocytosis which developed during treatment at the hospital and one case of agranulocytosis which developed in an out-patient. Patients in their care who had leukopenia as a result of an infection recovered from this symptom as soon as the infection was brought under control either by sulfanilamide, sulfapyridine, or some related drug. Long and Bliss, therefore, conclude that these drugs have no direct effect upon the white blood cells except that occasionally agranulocytosis may occur associated with the administration of these drugs.

Reference to a case cited by Ives (42) has been made earlier in which agranulocytosis associated with a hemolytic streptococcic angina improved after sulfanilamide was given. Long (63) also has said that sulfanilamide is indicated in those cases of leukopenia and agranulocytosis associated with an infection, for the removal of the infection will remove the etiological factor. It seems, however, that this opinion should be slightly modified. Strasser and Singer (96) say that if any disease which is characterized by leukopenia is treated by sulfanilamide or its
derivatives the depression of the white blood cells is apt to increase to an even still greater degree. He cites a case of miliary tuberculosis treated with prontosil in which agranulocytosis developed. This was treated with nucleotide and the white count rose. This argues for the cumulative effect of the drug. Later a 3 day course of treatment with the same drug resulted in total disappearance of granulocytes from the blood. The count rose after the drug had been discontinued and a transfusion had been given.

Agranulocytosis

The first cases of agranulocytosis associated with sulfanilamide and prontosil administration were reported by Plumer (101); Borst (8); and Young (108) in 1937. Each of these cases terminated fatally. After these accidents had occurred, more reports were made of both severe granulocytopenia and agranulocytosis resulting when this group of drugs were given.

Etiology. Long (62) thinks that the agranulocytosis which occurs and is associated with therapy by sulfanilamide or other members of the group is different from the type of reaction seen in the cases of agranulocytosis or profound granulocytopenia associated with aminopyrine. He bases this opinion on the fact that often
patients who have recovered from the disease do not subsequently develop granulocytopenia or other symptoms when test doses are given, or therapy is reinstituted for other infections. Schwentker (92) also has observed a lack of hypersensitivity to these drugs when they are administrated.

Jennings and Southwell (84) believe the condition of agranulocytosis following sulfanilamide administration is similar to the condition which occasionally occurs following the administration of benzol, toluol, and their nitro and amide products. They remind us of the fact that sulfanilamide and its related substances are members of this group of drugs. With amido-pyrine, however, it is not known how much of the drug is apt to cause an attack. With sulfanilamide, however, it has often been observed that after 20 grams have been administered in a period usually over 14 days the blood disturbances of the white cells are apt to occur. The fact that damage to the white cells does not occur until after a large amount of the drug has been given for a long time causes Shecket and Price (93), Taub and Lefkowitz (99) to think that it is the cumulative effect of the drug given over a long period of time that finally wears out the myeloid tissue of the bone marrow. Since large doses do not affect all patients in the same
manner it would seem that only the organically deficient marrows are affected.

Allen and Short (1), McGuire and McGuire (70), and Jones and Miller (49) have been able to report sensitivity to the drug by patients after they had recovered from agranulocytosis after a course of sulfanilamide treatment and therefore regard it as a reaction of the hematopoietic system of a hypersensitive nature.

Again we mention another factor previously cited (96), that one should proceed cautiously with the use of prontosil if there is already evidence of some white blood cell dyscrasia. One case of agranulocytosis which developed in a patient that had miliary tuberculosis was cited. Coxon and Forbes (15) reported a case of typhoid which developed an agranulocytosis after the patient had been treated with sulfapyridine. Four cases of whooping cough with bronchopneumonia, which were treated with sulfapyridine and also developed agranulocytopenia are reported by Dolgopol (24). All the diseases, tuberculosis, whooping cough and typhoid, are characterized by neutropenia and we wonder if the agranulocytosis which occurred may not have been influenced by the fact that changes already were present in the bone marrow before the drug therapy began.

Sex may or may not be a factor in the production
<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Total Age</th>
<th>Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Borst</td>
<td>Pyelocystitis</td>
<td>Female</td>
<td>61 gms.</td>
<td>Pront.</td>
<td>39</td>
<td>38 Days</td>
<td>960</td>
<td>None</td>
<td>Died</td>
</tr>
<tr>
<td>Allen</td>
<td>Bartholin Abscess</td>
<td>Female</td>
<td>18 gms.</td>
<td>Sulfan.</td>
<td>19</td>
<td>19 Days</td>
<td>2100</td>
<td>None</td>
<td>Recovery</td>
</tr>
<tr>
<td>Short</td>
<td>Rheumatic Fever</td>
<td>Female</td>
<td>12 gms.</td>
<td>Sulfan.</td>
<td>7</td>
<td></td>
<td>3200</td>
<td>Liver Ext. Transf.</td>
<td>Recovery</td>
</tr>
<tr>
<td>Berg Holtzman</td>
<td>Gonorrhea</td>
<td>Male</td>
<td>38.0 gms.</td>
<td>Sulfan.</td>
<td>27</td>
<td>27 Days</td>
<td>1600</td>
<td>1% Gran.</td>
<td>Died</td>
</tr>
</tbody>
</table>
### TABLE III
Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Age</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bresgen</td>
<td>Pyelitis</td>
<td>Female</td>
<td>80</td>
<td>33.62 gms.</td>
<td>21</td>
<td>21 Days</td>
<td>400</td>
<td>Transf. Liver Ext. Nucleotide X-Ray</td>
<td>Died</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Pront. &amp;</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Corr</td>
<td>1st Presc.</td>
<td>Female</td>
<td>55</td>
<td>35 gms.</td>
<td>15</td>
<td></td>
<td>800</td>
<td>Transf. Pentnucleotide</td>
<td>Died</td>
</tr>
<tr>
<td>Root</td>
<td>by Osteopa.</td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coxon</td>
<td>Typhoid</td>
<td>Female</td>
<td>22</td>
<td>54 gms.</td>
<td>17</td>
<td></td>
<td>100</td>
<td>Nucleinic Acid Calcium</td>
<td>Recovery</td>
</tr>
<tr>
<td>Forbes</td>
<td></td>
<td></td>
<td></td>
<td>Sulfapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Culbreath</td>
<td>Puerp.Sep.</td>
<td>Female</td>
<td>17</td>
<td>21.7 gms.</td>
<td>7</td>
<td>17 Days</td>
<td>700</td>
<td>Transf. Pentnucleotide</td>
<td>Died</td>
</tr>
<tr>
<td>Ellenton</td>
<td>Malaria</td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td>After last dose</td>
<td>0 Gran.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cutler</td>
<td>Salpingitis</td>
<td>Female</td>
<td>14</td>
<td>14 Days</td>
<td>1</td>
<td></td>
<td>1050</td>
<td>Transf. Pentnucleotide</td>
<td>Recovery</td>
</tr>
<tr>
<td>Crane</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE III
Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dolgopol</td>
<td>Pneumonia</td>
<td>Female</td>
<td>49 gms. Sulfa.py.</td>
<td>114</td>
<td>14 Days</td>
<td>2000</td>
<td>0 Gran.</td>
<td>Liver Ext.</td>
</tr>
<tr>
<td>Hobart</td>
<td>Pertussis</td>
<td>Female</td>
<td>27 gms. Sulfa.py.</td>
<td>15</td>
<td>3 Days</td>
<td>2500</td>
<td>0 Gran.</td>
<td>Liver Ext.</td>
</tr>
<tr>
<td>Dobgopal</td>
<td>Pertussis</td>
<td>Female</td>
<td>14.5 gms. Sulfa.pyr</td>
<td>14</td>
<td>4 Days</td>
<td>1200</td>
<td>24% Gran.</td>
<td>None</td>
</tr>
<tr>
<td>Hobart</td>
<td>Pneumonia</td>
<td>18 mos.</td>
<td>1100</td>
<td>11 Days</td>
<td>0 Gran.</td>
<td>Recovery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Evans</td>
<td>Pneumonia</td>
<td>Child</td>
<td>No Record Sulfa.py.</td>
<td>11</td>
<td>11 Days</td>
<td>1100</td>
<td>0 Gran.</td>
<td>--</td>
</tr>
<tr>
<td>Gaisford</td>
<td>Pneumonia</td>
<td>Male</td>
<td>77 gms. Sulfan.</td>
<td>17</td>
<td>2 Days</td>
<td>2000</td>
<td>24% Gran.</td>
<td>None</td>
</tr>
<tr>
<td>Adams</td>
<td>Meningitis</td>
<td>Male</td>
<td>45 gms. Sulfan.</td>
<td>21</td>
<td>21 Days</td>
<td>2000</td>
<td>0 Gran.</td>
<td>Yellow bone</td>
</tr>
<tr>
<td>Hall</td>
<td>Pneumonia</td>
<td>Male</td>
<td>9 Sulfan.</td>
<td>21</td>
<td>21 Days</td>
<td>2000</td>
<td>0 Gran.</td>
<td>Marrow Ext.</td>
</tr>
</tbody>
</table>
TABLE III
Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Age</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hoffman</td>
<td>G.C. Arthritis</td>
<td>Female</td>
<td>49.2</td>
<td>Sulfan. 18</td>
<td>3 Days</td>
<td>After last dose</td>
<td>0 Gran.</td>
<td>Transf. Liver Ext. Fe.Sulf.</td>
<td>Recovery</td>
</tr>
<tr>
<td>Trumper</td>
<td>Septic Mastoid</td>
<td>--</td>
<td>21</td>
<td>Streptoc. 12</td>
<td>35% Gran.</td>
<td>Withdrawal of Drug</td>
<td>Recovery</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hochmann</td>
<td>Gonorrhea</td>
<td>Male</td>
<td>7.2</td>
<td>Pront. 12</td>
<td></td>
<td>Drug discontinued because a drop occurred in the number of granulocytes on the 12th day. Decrease did not continue after drug discontinued.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ives</td>
<td>Septic sore throat with Agranulocytosis</td>
<td>Male</td>
<td>52</td>
<td>--</td>
<td>Before Drug</td>
<td>1200</td>
<td>Liver Ext. Soon as Drug</td>
<td>Recovery</td>
<td></td>
</tr>
<tr>
<td>Johnston</td>
<td>Puerperal Sepsis</td>
<td>Female</td>
<td>61.3</td>
<td>Sulfan. 20</td>
<td>20 Days</td>
<td>0 Gran.</td>
<td>1520</td>
<td>Transf. Pentnucle.</td>
<td>Recovery</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
TABLE III
Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Johnston</td>
<td>Puerperal</td>
<td>Female</td>
<td>68.45 gms.</td>
<td>22</td>
<td>22 Days</td>
<td>3500</td>
<td>Transfs. Pentnucle.</td>
<td>Recovery</td>
</tr>
<tr>
<td></td>
<td>Sepsis</td>
<td></td>
<td>Front. &amp; Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td>5 Tab. Allowed</td>
<td></td>
</tr>
<tr>
<td>Jones</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Miller</td>
<td>Gonorrhea</td>
<td>Male</td>
<td>30 gms.</td>
<td>20</td>
<td>20 Days</td>
<td>2500</td>
<td>Yellow bone Marrow conc.</td>
<td>Recovery</td>
</tr>
<tr>
<td>Marcus</td>
<td>Pyelitis</td>
<td>Female</td>
<td>16.25 gms.</td>
<td>25</td>
<td>25 Days</td>
<td>1000</td>
<td>Transfs. Pentnucle. Bone Marrow</td>
<td>Recovery</td>
</tr>
<tr>
<td>McGuire</td>
<td>Arthritis</td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td>0 Gran.</td>
<td>Symp. Recur Pentnucle. with Drug</td>
<td></td>
</tr>
<tr>
<td>Model</td>
<td>Rheum. Fever</td>
<td>Male</td>
<td>54 gms.</td>
<td>18</td>
<td>18 Days</td>
<td>300</td>
<td>Transfs. Pentnucle.</td>
<td>Died</td>
</tr>
<tr>
<td></td>
<td>Endocar.</td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td>0 Gran.</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Reference</td>
<td>Diagnosis</td>
<td>Sex</td>
<td>Age</td>
<td>Total Drug</td>
<td>Total Days</td>
<td>Onset of Diagnosis</td>
<td>Lowest W.B.C.</td>
<td>Treatment</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------</td>
<td>------</td>
<td>-------</td>
<td>-------------</td>
<td>------------</td>
<td>-------------------</td>
<td>--------------</td>
<td>-----------------------</td>
</tr>
<tr>
<td>Pearson</td>
<td>Sinusitis</td>
<td>Female</td>
<td>60</td>
<td>Front.</td>
<td>6 Days</td>
<td>6 Days After Last Dose</td>
<td>600</td>
<td>Transf. from Leukemia</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Album.</td>
<td>24</td>
<td></td>
<td></td>
<td>Patient</td>
</tr>
<tr>
<td>Flumer</td>
<td>Subacute Bacterial Endocarditis</td>
<td>Female</td>
<td>43.25 gms.</td>
<td>Sulfan.</td>
<td>3 Days</td>
<td>3 Days After Last Dose</td>
<td>400</td>
<td>None</td>
</tr>
<tr>
<td>Sailor</td>
<td>Subacute Bact. Endocard.</td>
<td>Male</td>
<td>59</td>
<td>Sulfan.</td>
<td>23</td>
<td>23 Days</td>
<td>200</td>
<td>None</td>
</tr>
<tr>
<td>Schwartz</td>
<td>Chancroidal Ulcer</td>
<td>Male</td>
<td>56 Gms.</td>
<td>Sulfan.</td>
<td>21</td>
<td>18 Days</td>
<td>300</td>
<td>Pentnucle.</td>
</tr>
<tr>
<td>Koletsky</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>0 Gran.</td>
<td>Liver Ext. Transf.</td>
</tr>
<tr>
<td>Schwartz</td>
<td>Gonorrheal Arthritis</td>
<td>Male</td>
<td>66 gms.</td>
<td>Sulfan.</td>
<td>13</td>
<td>13 Days</td>
<td>1350</td>
<td>Pentnucle.</td>
</tr>
<tr>
<td>Garvin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>20% Gran.</td>
<td>Liver Ext. Transfs.</td>
</tr>
<tr>
<td>Koletsky</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Died</td>
</tr>
</tbody>
</table>
### TABLE III

**Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis**

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Schwartz</td>
<td>Erysipelas</td>
<td>Female</td>
<td>15 gms.</td>
<td>3</td>
<td>3 Days</td>
<td>2000</td>
<td>Pentnucle.</td>
<td>Liver Ext.</td>
</tr>
<tr>
<td>Garvin</td>
<td>Epigastrium</td>
<td>Female</td>
<td>100 gms.</td>
<td>17</td>
<td>19 Days</td>
<td>400</td>
<td>Pentnucle.</td>
<td>Liver Ext.</td>
</tr>
<tr>
<td>Koletsky</td>
<td>Erysipelas</td>
<td>Female</td>
<td>15 gms.</td>
<td>15</td>
<td>15 Days</td>
<td>50</td>
<td>Pentnucle.</td>
<td>Transfs.</td>
</tr>
<tr>
<td>Koletsky</td>
<td>Erysipelas</td>
<td>Female</td>
<td>52 gms.</td>
<td>3</td>
<td>3 Days</td>
<td>1200</td>
<td>Pentnucle.</td>
<td>Liver Ext.</td>
</tr>
<tr>
<td>Price</td>
<td>Pneumonia</td>
<td>Male</td>
<td>61/2 gms.</td>
<td>15</td>
<td>15 Days</td>
<td>0 Gran.</td>
<td>Pentnucle.</td>
<td>Transfs.</td>
</tr>
<tr>
<td>Shullenberger</td>
<td>Throat</td>
<td>Male</td>
<td>52.39 gms.</td>
<td>21</td>
<td>3 Days</td>
<td>0 Gran.</td>
<td>Pentnucle.</td>
<td>Recovery</td>
</tr>
<tr>
<td>Shullenberger</td>
<td>Throat</td>
<td>Male</td>
<td>52 gms.</td>
<td>12</td>
<td>3 Days</td>
<td>1500</td>
<td>Pentnucle.</td>
<td>Transfs.</td>
</tr>
<tr>
<td>Sutherland</td>
<td>Spesis</td>
<td>37</td>
<td>52 gms.</td>
<td>12</td>
<td>3 Days</td>
<td>0 Gran.</td>
<td>Pentnucle.</td>
<td>Recovery</td>
</tr>
<tr>
<td>Reference</td>
<td>Diagnosis</td>
<td>Sex</td>
<td>Age</td>
<td>Total Drug</td>
<td>Total Days</td>
<td>Onset of Diagnosis</td>
<td>Lowest W.B.C.</td>
<td>Treatment</td>
</tr>
<tr>
<td>-----------</td>
<td>----------------------------</td>
<td>-----</td>
<td>-----</td>
<td>------------</td>
<td>------------</td>
<td>--------------------</td>
<td>--------------</td>
<td>-------------------------</td>
</tr>
<tr>
<td>Sweeney</td>
<td>Sore Throat</td>
<td>Female</td>
<td>41</td>
<td>18 gms.</td>
<td>8</td>
<td>Had taken previously</td>
<td>1800</td>
<td>Daily Transfs.</td>
</tr>
<tr>
<td>Taub</td>
<td>Pneumonia</td>
<td>Female</td>
<td>66</td>
<td>44 gms.</td>
<td>31</td>
<td>After last dose</td>
<td>1000</td>
<td>Transfs.</td>
</tr>
<tr>
<td>Lefkowitz</td>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td>Pentnucle.</td>
</tr>
<tr>
<td>Rosenthal</td>
<td>Recurrent Pneumonia</td>
<td>Male</td>
<td>1</td>
<td>15.25 gms.</td>
<td>?</td>
<td>During 4th Week</td>
<td>1000</td>
<td>Liver Ext. Transfs.</td>
</tr>
<tr>
<td>Vogel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenthal</td>
<td>Osteomyelitis</td>
<td>Male</td>
<td>10</td>
<td>95 gms.</td>
<td>17 Days</td>
<td>0 Gran.</td>
<td>300</td>
<td>Transf.</td>
</tr>
<tr>
<td>Vogel</td>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rosenthal</td>
<td>Pertusis &amp; Bronchopneum.</td>
<td>Female</td>
<td>42</td>
<td>42 gms.</td>
<td>16</td>
<td>16 Days</td>
<td>1100</td>
<td>Transf.</td>
</tr>
<tr>
<td>Vogel</td>
<td></td>
<td></td>
<td></td>
<td>Sulfan.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### TABLE III

Tabulation of Reported Cases of Granulocytopenia and Agranulocytosis

<table>
<thead>
<tr>
<th>Reference</th>
<th>Diagnosis</th>
<th>Sex</th>
<th>Age</th>
<th>Drug</th>
<th>Total Drug</th>
<th>Total Days</th>
<th>Onset of Diagnosis</th>
<th>Lowest W.B.C.</th>
<th>Treatment</th>
<th>Outcome</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jennings</td>
<td>Ulcerative Colitis</td>
<td>Female</td>
<td>39</td>
<td>Sulfan</td>
<td>94 gms.</td>
<td>21</td>
<td>3 Days After last dose</td>
<td>1800</td>
<td>Pentnucle.</td>
<td>Died</td>
</tr>
<tr>
<td>Southwell-Sander</td>
<td>Ulcerative Colitis</td>
<td>Male</td>
<td>53</td>
<td>Pront. Alb.</td>
<td>54 gms.</td>
<td>18</td>
<td>3 Days After last dose</td>
<td>0 Gran.</td>
<td>Recovery</td>
<td></td>
</tr>
</tbody>
</table>

* * * * *
of this condition. This is suggested since in the 46 cases listed in Table III, 26 are females and 15 are males. Two cases are not listed as to sex.

Possible etiological factors considered which may play a part in the development of the agranulocytopenia are bone marrow damage by previous infection, bone marrow changed by cumulative effect of long continued drug therapy, sex, abnormality of bone marrow of obscure origin, idiosyncrasy to drugs. That various factors may be concerned is evident, but the mechanism of the production of this abnormality remains unknown as in the case of other drug idiosyncrasy. A typical geographical distribution is not apparent in the case of this drug idiosyncrasy because the drug is so universally used and not confined so closely to Germany, United States, and Denmark as was the case with aminopyrine. Cases are also reported from France (79) and from other countries. The class distribution also does not hold for the sulfanilamide group because it is used for treating the infections of every class of people.

Pathology. The pathology of the bone marrow is reported in Table IV. As in agranulocytosis associated with other drugs, the findings vary.
<table>
<thead>
<tr>
<th>Author</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bresgen</td>
<td>Decrease in myeloid cells. Increase in lymphocytes.</td>
</tr>
<tr>
<td>Dolgopol</td>
<td>Slight decrease in the nucleated cellular elements. Most cells immature.</td>
</tr>
<tr>
<td></td>
<td>Prominence of reticulo-endothelial cells. Many lymphocytes and megakaryocytes.</td>
</tr>
<tr>
<td>Pearson</td>
<td>Many mononuclear cells. No segmented cells. Immature and developing erythrocytes.</td>
</tr>
<tr>
<td>Sailor</td>
<td>Hyperplastic and aplastic changes.</td>
</tr>
<tr>
<td></td>
<td>Aplastic changes were most marked. No areas of erythrocyte destruction.</td>
</tr>
<tr>
<td>Shecket</td>
<td>Myeloblastic arrest.</td>
</tr>
<tr>
<td>Young</td>
<td>Bone marrow aplasia.</td>
</tr>
</tbody>
</table>
**Course of Disease.** See Table III for information concerning reports of cases of severe granulocytopenia and agranulocytosis. The one symptom and finding associated most often with this condition is fever, which is an important warning signal of so many of the severe toxic effects of the sulfanilamide group of drugs. Fever usually precedes skin eruptions, toxic hepatitis, as well as agranulocytosis. Other warning signals which may or may not be a sign of beginning of this severe disturbance is a fever which continues even though the symptoms and signs of the original infection have disappeared, eruptions, gradual but slow decrease in the hemoglobin, and any abrupt rise or fall in the white blood count.

Table III is a tabulated record of available case reports in the literature. From a study of the cases we find that in addition to the fever associated with both the onset and the course of the disease there are chills, malaise, abdominal pains, sore throat, extreme toxicity, weakness, headache, confusion, and a foul breath. There is always leukopenia with profound granulocytopenia which may result in complete disappearance of all granulocytes. There may or may not be angina.

The reports of cases cited from the table indicate that the withdrawal of the drug does not always halt the progressive drop in white blood cells immediately.
but the counts often continue to drop 2 or 3 days after the last dose. The count may not drop until a few days after the last dose is given. Often a steady but slow decrease in the total white count with no disturbance of ratio of different cells is a sign of the beginning of the dyscrasia. Twenty-six cases occurred in females, 15 in males. In two instances the sex is not stated. There is no predominence of any age group. No single type of infection predominates. The total dose of the drug ranges from 14.5 to 100 grams in a period of 7 to 39 days. With two exceptions the onset ranges from 14 to 21 days after the beginning of the drug's administration. Sulfanilamide, sulfapyridine, and prontosil had been used in various instances. Of the 43 reported cases, 18 were fatal.

Treatment. Treatment of white blood cell dyscrasias associated with drugs of the sulfanilamide
group is both prophylactic and active.

The best way to avoid the development of agranulocytosis associated with the para-amino-benzene sulfonamide drugs would be not to give the drug. Since that is impossible because these drugs are valuable aids in saving lives, it is necessary that the drug should not be given unless there exists an indication for its use. When it is used, the course of the patient's illness should be carefully watched. Fever, rash, slowly progressing anemia, slow response to treatment, gradual decreasing white blood count with or without neutropenia should all be regarded as warning signals. Other warning signals are development of jaundice, and any abrupt rise or fall in white blood cells.

Shecket and Price (93) say that if the efficacy of one of these drugs in combatting the infection is not demonstrated from four to seven days after the beginning of the administration, the drug should not be continued, for they believe the prolonged administration and the consequent large amounts of drug result in a cumulative toxic effect. Along this same line of thought is Bresgen's (9) advice to give large doses of the drug for a short time and thereby avoid the long continued effect of the drug upon the myeloid elements. He also
says that too small inadequate doses do not stop the infection but keep up a chronic low grade type of infection which results in added strain upon the bone marrow along with the effect of the drug. Schecket and Price (93) also remind us that the fact that the drug has been discontinued does not absolve us from continuing to watch the patient carefully, for often the agranulocytosis does not show itself until several days after the last dose of the drug. (96)

If there is already depressed or a changed bone marrow due to the nature of an infectious disease or other toxic factors, the question of whether or not to administer sulfanilamide should be carefully considered.

Carr and Root (14) advise that the physician and nursing staff be very watchful as long as the patient is on the drug, but especially so after 14 days have elapsed and the patient continues to receive it. Whenever a white count has been reduced to 3000 or 4000 the drug should be discontinued immediately and the patient carefully watched. (84) Hohmann (41) advises cessation of the drug therapy whenever the granulocytes are decreased even though the total white count has not decreased.

After having considered the various suggestions
made which are all valuable in the prevention of serious blood dyscrasias, it is evident that it is very foolish to prescribe these drugs for every ache and pain. At this time the indications for the use of these drugs are well established both by clinical investigation and experience as well as by experimental work, and the medical profession contributes most to prophylaxis of severe toxic effects upon the blood by not using the drug ill-advisedly.

If agranulocytosis has occurred during or immediately following the ingestion of the sulfanilamide group of drugs, the drug must be discontinued at once if not already done. Elimination from the body is aided by forcing fluids. (68)(95)

Anemia is usually not associated with agranulocytosis. Blood transfusions should be made if anemia is part of the picture. The transfusions, however, do not stimulate the bone marrow and the relatively few leukocytes added to the circulation are of little or no help for they are rapidly used. X-Ray over the long bones has been suggested to depress the bone marrow but this has been abandoned as well as the theory that if sepsis or necrosis is induced the need for leukocytes will stimulate their production or maturation.(27)(43)(44)

Doan (23) says that nucleic acid exerts a
chemotactic effect upon normal myeloid foci and causes a prompt effective increase in the delivery of leukocytes to the peripheral vascular system. He does not believe that spontaneous recovery occurs from agranulocytosis because he thinks it is due to an intrinsic deficiency phenomenon. The nucleic acid and nucleotides supply the stimulus of maturation and the stimulus of initiation of development of cells to mature leukocytes if the bone marrow is in a condition to respond. (80)(81) If the condition has progressed to such a stage that the marrow has become aplastic, it will be impossible for it to be stimulated by any products of nucleic acid. Hall (35) suggests yellow bone marrow extract, because it supposedly supplies the intrinsic factor which is able to cause the bone marrow to produce mature cells and deliver them to blood. Yellow bone marrow extract is given orally in capsules containing 3.5 grains. Fifty to one hundred capsules are given daily until monocytes appear in the blood, and monocytes' reappearance in the blood stream are said to be of favorable prognostic significance. If adenine sulfate is used it is suggested that 1 gram be given intramuscularly three times a day until an increase in neutrophils begins. Jackson (43) advises pentnucleotide, 10 cc. intravenously four times a day. He has had very
good results with this substance.

From the cases reviewed, the best routine followed in treating agranulocytosis is to exclude the drug immediately and hasten its rapid excretion. Blood transfusion is necessary if the hemoglobin is less than 60%. Since it is not known what type of mechanism is responsible for the dyscrasia, it seems that no harm is done by using some form of a nucleotide or liver extract. The diet should be complete and the patient given good nursing care.

**Hyperleukocytosis.**

Before leaving the discussion of white blood cell disturbances, a few reports of hyperleukocytosis have been made. Fitzhugh (27) and Alpert (2) have found this condition to occur especially associated with drug fever and rash. A similar reaction has been noticed in laboratory animals. (64)
SUMMARY

1. A review of the literature concerning the disturbances of the erythrocytes and leukocytes of the blood associated with the administration of para-aminobenzene sulfonamide and its derivatives has been made.

2. Both a chronic slowly-developing hemolytic anemia and an acute hemolytic anemia are occasionally associated with the administration of these drugs.

3. Agranulocytosis and leucopenia are also associated with the ingestion of these drugs.

4. These hematological dyscrasias are very similar to the sensitivity reactions caused by aminoypyrine and other drugs of the amino benzene group of drugs.

5. Possible etiological factors which may be concerned in the development of these types of drug idiosyncrasy are size of the dose of the drug, the length of time the drug is given, the sex of the patient, the effect of the infectious process which is being tested, and the cumulative effect of the drug.
6. The actual mechanism of the production of the anemia is not known, nor is the mechanism of the production of agranulocytosis understood.

7. There is no typical characteristic bone marrow picture associated with these conditions.

8. The promiscuous use of the drugs of the para-amino-benzene sulfonamide group is to be discouraged. This applies to the medical profession as well as to the laymen.

9. Whenever the drug has been prescribed for a patient, the patient should be closely observed during the course of the drug therapy. If the response is not favorable, the drug should not be continued over too long a period of time.

* * * * * * *

- 57 -
BIBLIOGRAPHY

1. Allen, J. G.; Short, C.L.
Granulocytopenia Associated with Sulfanilamide Therapy.
New Eng. J. Med. 219:6-8, July 1938

2. Alpert, G.R.; Forbes, R.P.
Granulocytopenia and Hyperleukocytosis Following Sulfanilamide Therapy
J. Pediatrics 12:605-609, May 1938

3. Antopol, William; Robinson, Harry
Pathologic and Histologic Changes Following Oral Administration of Sulfapyridine
Arch. Path. 29:67-76, 1940

4. Antopol, W.; Applebaum, Goldman L.
Acute Hemolytic Anemia with Autoagglutination Following Sulfanilamide Therapy
J. A.M.A. 113:488-489, Aug. 1939

5. Barnett, H.L.; Hartmann, A.F.; Perley, A.M.; Ruhoff, Mary E.
The Treatment of Pneumococcal Infections in Infants and Children with Sulfapyridine
J. A.M.A. 112:518-527, 1939

6. Berg, Samuel; Holtzman, Michael
Fatal Granulocytopenia Following Sulfanilamide Therapy

7. Bigler, J.A.; Clifton, W.M.; Werner, M.
The Leukocyte Response to Sulfanilamide Therapy
J. A.M.A. 110:343-349, Jan. 1938

8. Borst, J.C.G.
Death from Agranulocytosis After Treatment with Prontosil Flavum
Lancet I:1519-1520, 1937

9. Bresgen, C.
Zur Ätiologie der Agranulocytose
Action of Sulfanilamide on Leukocytes.
Lancet, II + 718-720, Sept. 1938

Deuring, T.; Foster, G.C.
Treatment of Streptococcal Infections in Mice
with 4:4' Diaminodiphenylsulphone.
Lancet, I:1331-1334, June 1937

12. Campbell, C.M.
Effect of Sulfanilamide on the Blood Picture,
Lancet I:247-248, Jan. 1938

13. Colebrook, L.; Kenny, M.
Treatment of Human Puerperal Infections in Mice
with Prontosil
Lancet I:1270-1286, 1936

14. Corr, P.; Root, R.N.
Death from Granulocytopenia after Sulfanilamide Therapy
J.A.M.A. 112:1939-1940, May 1939

15. Cbxon, R.V.; Forbes, J.R.
Agranulocytic Angina Following Administration
of M and B 693 (Sulfapyridine)
Lancet 2:1412-1413, Dec. 1938

16. Culbreath, Paul; Ellenton, S.C.
Fatal Case of Agranulocytosis Following Therapy

17. Cutler, I.L.; Crane, E.J.
Agranulocytosis Caused by Sulfanilamide
Recovered Case

18. Danziger, L.
Delayed Toxic Reaction of Sulfanilamide

19. Domagk, Gerhard
Ein Beitrag zur Chemotherapie der Bakteriellen Infection
20. Domagk, G.
Chemotherapie der Streptokokken Infektionem

21. Domagk, G.
Der derzeitige Stand der Chemotherapie der
bakteriellen Infektionen

22. Darling, R.C.; Parker, F.Jr.; Jackson, H. Jr.
The Pathological Changes in Bone Marrow in
Agranulocytosis.
Am.J.Path. 12:1-12, 1936

23. Doan, C.A.
The Neutropenic State: Its Significance and
Therapeutic Rationale
J.A.M.A. 99:194-202, 1932

24. Dolgopol, V.B.; Hobart, H.M.
Granulocytopenia (and Leukopenia) in Sulfapyridine Therapy
J.A.M.A. 113:1012-1017, Sept. 1939

25. Evans, G.M.; Gainsford, Wilfrid F.
Treatment of Pneumonia with 2-(p-aminobenzene-
sulphonamido) pyridine
Lancet II:14-19, July 1938

26. Finkelstone-Sayliss, R.; Paine, C.G.;
Patrick, L.B.
Bacteriostatic Action of p-amino Benzene
Sulfonamide upon Hemolytic Streptococcus
Lancet II: 792-796, Oct. 1937

27. Fitz-Hugh, T. Jr.
Sensitivity Reactions of Blood and Bone Marrow
to Certain Drugs
J.A.M.A. 111:1643-1647, 1938

28. Fitz-Hugh, T. Jr.; Krumbhaar, E.B.
Myeloid Cell Hyperplasia of the Bone Marrow
in Agranulocytic Angina
Am.J.Path. 183:104-110, 1932

29. Flippin, H.F.; Lockwood, J.S.; Pepper, D.S.;
Schwartz, Leon
The Treatment of Pneumococcic Pneumonia with
Sulfapyridine
J.A.M.A. 112:529, 1939
30. Garvin, C.F.
Complications Following Administration of Sulfanilamide
J.A.M.A. 113:288-291, July 1939

31. Gray, R.C.; Adams, B.
Treatment of Pneumococcal Meningitis with Sulfanilamide and Specific Serum. Case with Agranulocytosis and Recovery.
Minnesota Medicine 22:369-373, June 1939

32. Hageman, P.O.
Clinical Experience in the Use of Sulfanilamide at the New Haven Hospital
Jour.Pediat. 11:195, August 1937

33. Hageman, P.O.
Toxicity of Sulfanilamide. Study of Pathological Lesions in White Mice

34. Hageman, P.O.; Blake, Francis, C.
Clinical Experience with Sulfanilamide in the Treatment of beta-Hemolytic Streptococcus Infections

35. Hall, B.E.
Influence of Sulfanilamide on Blood
Proc.Staff Meet.of Mayo Clinic 14:155-157, 1939

36. Hawking, F.
Pharmacologic Actions of Sulphanilamide
Lancet II:1019-1021, Oct. 1937

37. Higgins, C.M.; Machella, T.E.
Anemia Induced by Sulfanilamide in the Presence of Nicotinic Acid

38. Harvey, A.M.; Janeway, C. A.
The Development of Acute Hemolytic Anemia

39. Hodes, E.L.; Stifler, W.C.; Walker, Ethel; McCarty, Marcyn; Shirley, R.G.
The Use of Sulfapyridine in Primary Pneumococcal Pneumonia
J.Pediat. 14:417-446, 1939
40. Hoffman, B.J.
Post-sulfanilamide Agranulocytosis Case with Recovery
J.M.A. Georgia 23:166+167, April 1939

41. Hohmann, W.J.
Control of Sulphanilamide Therapy
Brit. M.J. I:923, 1938

42. Ives, R.F.
Hemolytic Streptococcic Angina with Agranulocytosis. Treated with Prontosil and Sulfanilamide.

Agranulocytosis: Its Etiology and Treatment

44. Jackson, Henry Jr.; Tighe, Thomas, J.C.
An Analysis of the Treatment and Mortality of Three Hundred and Ninety Cases of Acute Agranulocytic Angina

45. Jackson, H. Jr.
The Differential Diagnosis of Agranulocytic Angina from Acute Leukemia
Am.J.M.Sc. 188:604-608, 1934

46. Jennings, G.H.; Southwell-Sander, G.
Anemia and Agranulocytosis During Sulphanilamide Therapy
Lancet II:898-902, 1937

47. Johannsen, M.W.; St.George, A.V.
Toxicity and Therapeutic Effects of Sulfapyridine in Animals

48. Johnston, F.D.
Granulocytopenia Following Administration of Sulphanilamide Compounds.
Lancet 2:1044-1047, Nov. 1938

49. Jones, H.W.; Miller, C.P.
Neutropenia Following Sulfanilamide
50. Keefer, C.S.  
Sulfanilamide: Its Mode of Action and Use in  
the Treatment of Various Infections  

51. Kohn, S.E.  
Acute Hemolytic Anemia during Treatment with  
Sulfanilamide  
J.A.M.A. 109:1005, 1937

52. Koletsky, S.  
Fatal Hemolytic Anemia following Administration  
of Sulfanilamide  
J.A.M.A. 113:291-294, July 1939

53. Kracke, R.R.  
A Review of Granulocytopenia  

54. Kracke, R.R.  
The Experimental Production of Agranulocytosis  

55. Kracke, R.R.; Parker, F.P.  
The Etiology of Granulopenia (Agranulocytosis)  
with Particular Reference to Drugs Containing  
the Benzene Ring.  

56. Kracke, R.R.  
Relation of Drug Therapy to Neutropenic States  

57. Kreutzman, W.B.; Corr, J.L.  
The Effect of Prontosil on Blood Cells  

58. Lloyd, V.E.; Erskine, D. and Johnson, A.G.  
Chemotherapy of Gonorrhea with M & B 693  
Lancet II:1160-1164, Nov. 1938

59. Long, P.H.; Bliss, E.A.  
Toxic Manifestations  

60. Long, P.H.; Bliss, E.A.  
The Clinical Use of Sulfanilamide and Its  
Derivatives in the Treatment of Infectious  
Diseases.  
Annals of Int.Med. 11:575-591, Nov.1937
61. Long, P.H.; Bliss, E.A.; Feinstone, W.H.
Mode of Action, Clinical Use and Toxic Manifestations of Sulfanilamide
J.A.M.A. 112:115-121, Jan. 1939

62. Long, P.H.; Bliss, Eleanor
Clinical Use of Sulfanilamide and Sulfapyridine and Allied Compounds
MacMillan Company, New York, 1939

63. Long, P.H.; Bliss, E.A.; Feinstone, W.H.
Effects of Sulfapyridine, Sulfanilamide, and Related Compounds in Bacterial Infections

64. Loseke, L.
Constitutional Changes in Rabbits Subjected to Combined and Uncombined Fever and Sulfanilamide Therapy
Thesis: Presented to Graduate Faculty, University of Nebraska, College of Medicine, 1940.

65. Machella, T.E.; Higgins, G.M.
Anemia Induced in Rats by the Administration of Sulfanilamide

66. Madison, F.W.; Squier, T.L.
The Etiology of Primary Granulocytopenia (Agranulocytic Angina)
J.A.M.A. 102:755-759, 1934

67. Marcus, N.L.
Agranulocytosis and Sulfanilamide
J.Florida M.A. 25:489-496, April 1939

The Renal Excretion of Sulfanilamide

The Toxicity of Sulfanilamide
J.A.M.A. 110:252-257, Jan.1938

70. McGuire, P.R.; McGuire, J.P.
Agranulocytosis Following Use of Sulfanilamide
Ill.M.J. 73:425-426, May 1938
71. Model, A.  
Agranulocytosis and Para-amino-benzene-sulfonamide  

72. Molitor, Hans; Robinson, H.  
Acute, Cumulative and Chronic Toxicity of  
Sulfapyridine  
J. Pharm. & Exper. Therap. 65:405-423, April 1939.

73. Nelson, A.A.  
Histopathologic Changes in Hens and Rabbits  
Following Administration of Sulfanilamide and  
Sulfanilyl Sulfanilamide  
Pub. Health Reports.

74. Nelson, E.L.; Scott-Young, M.  
Profound Anemia Following Administration of  
Sulfanilamide in Acute Gonorrhea  
Med. Jour. Australia 1:626-627, April 1938

75. Pearson, H.E.S.  
Fatal Agranulocytosis after Sulfonilamide  
Treatment  
Brit. M. J. 1:1031-1032, May 1939

76. Pepper, O.H.R.  
Leukopenia: A Review with Special Reference  
to Agranulocytic Angina  
Calif. and Western Med. 35:173-177, 1931  
35:82-86, 1931

77. Plumer, H.E.  
Prontylin and Frontosil  

78. Posner, I.; Guthrie, N.W.; Mattice, M.R.  
Formation of Abnormal Blood Pigment as a Compli-  
cation of Sulfanilamide Therapy.  

79. Ravinia, A.  
Indications et Accidents du Para-amino-phenyl-  
sulfamide  
Presse Med. 46:332-336, March, 1938

80. Reznikoff, P.  
Nucleotide Therapy in Agranulocytosis  
81. Richmond, E.L.  
Granulocytopenia Following Surgical Sepsis and Treated with Adenine Sulfate  

82. Rimington, C.  
Porphyrinuria Following Sulfonilamide Dermatitis.  
Lancet 1:770-776, April 1938.

83. Rosenblum, P.; Rosenbaum, A.H.  
Severe Hemolytic Anemia Due to Sulfanilamide  

84. Rosenthal, N.; Vogel, P.  
Granulocytopenia Caused by Sulfapyridine  

85. Rosenthal, N.  
Hematological Aspects of Agranulocytosis and Other Diseases Accompanied by Extreme Leukopenia  

86. Rosenthal, S. M.  
Effects of Repeated Administration of Sulfanilamide and Sulfanilyl Sulfanilamide to Rabbits and Chickens  

87. Rosenthal, S. M.; Bauer, Hugo  
Colorimetric Tests for Aromatic Hydroxylamines and for Further Oxidation Products of Aromatic Amines. Their Demonstration in the Urine Following Sulfanilamide Administration  

88. Sailor, Seaton  
Subacute Bacterial Endocarditis Treated with Sulfanilamide Resulting in Granulocytopenia and Death  

89. Schilling, V. The  
The Blood Picture, Translation by R. Graiwohl  
C. V. Mosby, St. Louis, 1929.

90. Schultz, W.  
Über eigenartige Halserkrankungen  
Deutsche med. Wchnschr. 48:1495-1499, 1922.
91. Schwartz, Walter F.; Garvin, C.F.; Koletsky, Simon
Fatal Granulocytopenia from Sulfanilamide
J.A.M.A. 110:368-370, Jan. 1938

92. Schwentker, F. F.
Use of Sulfanilamide in Treatment of Infections

93. Shecket, H.A.; Price, A.E.
Fatal Granulocytopenia following Administration
of Sulfanilamide
J.A.M.A. 112:823-828

94. Shullenberger, W.A.
Agranulocytosis following Treatment of Bacterial
Infections with Sulfapyridine
J.Indiana M.A. 32:415-417, Aug. 1939

95. Stewart, J.D.; Rourke, G.M.; Allen, J.G.
Excretion of Sulfanilamide
J.A.M.A. 110:1835-1837, 1938

96. Strasser, A.; Singer, K.
Ueber Prontosil-Hemoglobinurie und Andere
Sulfanilamid-Blutschaedigungen
Med.Klin. 34:783-784, June 1938

97. Sutherland, M.E.
Agranulocytosis following Administration of
M & B 693 (Sulfapyridine)
Lancet I:1208-1209, May 1939

98. Sweeney, Shirley J.; Allday, L.E.
Granulocytopenia from Sulfanilamide with Unusual
Blood Crisis and Recovery

99. Taub, J.; Lefkowitz, L.
Agranulocytosis due to Sulfanilamide

100. Trefouel, J.; Trefouel, J. Mme.; Nitti, F.;
Bouet, D
Activite du p-amino phenylsulfamide sur les
Infections Streptococcique Experimentales de
la Souris et du Lapin
Comp.rend.Soc.de Biol. 120:756, 1935
101. Trumper, A.
  Prontylin and Prontosil

102. Van Duyn, J.
  Leukocyte Exhaustion Following Surgical Procedure
  Arch. Surg. 37:302-310, 1938

103. Whitby, L.E.H.
  Discussion on Use of Sulfanilamide and Allied Drugs in Treatment of Human and Animal Diseases.

104. Wien, R.
  Toxicity of (p-aminobenzenesulphonamido) Pyridine.
  Quant. J. Pharm. and Pharmacol. 11:217-224, 1938

105. Willis, Thayer
  Sulfanilamide in Ophthalmia Neonatorum
  Yale Jour. Biol. and Med. 10:275, Jan. 1938

  Anemia During Therapy
  J. A. M. A. 111:1916-1919, Nov. 1938

107. Wood, H.
  Fatality from Acute Hemolytic Anemia which Developed During Administration of Sulfanilamide
  South. Med. Jour. 31:646-648, June 1938

108. Young, C.J.
  Agranulocytosis and Para-amino-benzine-Sulphonamide